ArticleFrontiers in bioengineering and biotechnology2020
Successful Use of Human AB Serum to Support the Expansion of Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell in a Microcarrier-Based Platform.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Scaling the manufacture of adipose tissue-derived mesenchymal stromal cells: integrated bioreactor workflows from inoculation to harvest without the need of seed train.BMC biotechnology · 2026Article
- A fluffy nanofiber scaffold-based microenvironment enables a simplified, biology-centric scale-up strategy for mesenchymal stem/stromal cell culture.Frontiers in bioengineering and biotechnology · 2026Article
- Limbal stem cell sheet bandage for short-term treatment of corneal regeneration.BMC ophthalmology · 2025Article
- Continuous collection of human mesenchymal-stromal-cell-derived extracellular vesicles from a stirred tank reactor operated under xenogeneic-free conditions for therapeutic applications.Stem cell research & therapy · 2025Article
- Identification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs.Frontiers in bioengineering and biotechnology · 2025Review
- Comparative Analysis of Serum and Serum-Free Medium Cultured Mesenchymal Stromal Cells for Cartilage Repair.International journal of molecular sciences · 2024Article
- Towards Stem Cell Therapy for Critical-Sized Segmental Bone Defects: Current Trends and Challenges on the Path to Clinical Translation.Journal of functional biomaterials · 2024Review
- Treatment of medication-related osteonecrosis of the jaw with cell therapy.Frontiers in cell and developmental biology · 2024Article
- Adipose-derived stem cells (ASCs) culture in spinner flask: improving the parameters of culture in a microcarrier-based system.Biotechnology letters · 2023Article
- Hypothermic Preservation of Adipose-Derived Mesenchymal Stromal Cells as a Viable Solution for the Storage and Distribution of Cell Therapy Products.Bioengineering (Basel, Switzerland) · 2022Article
- Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.Frontiers in bioengineering and biotechnology · 2022Review
- Bioprocessing of Human Mesenchymal Stem Cells: From Planar Culture to Microcarrier-Based Bioreactors.Bioengineering (Basel, Switzerland) · 2021Review
- Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products.The Biochemical journal · 2020Review
- Influence of Microenvironment on Mesenchymal Stem Cell Therapeutic Potency: From Planar Culture to Microcarriers.Frontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and for the promotion of tissue repair, hence the increase of clinical trials in a worldwide scale. In particular, adipose tissue-derived stem/stromal cells (AT MSC) present easy accessibility and a rather straightforward process of isolation, providing a clear advantage over other sources. The high demand of cell doses (millions of cells/kg), needed for infusion in clinical settings, requires a scalable and efficient manufacturing of AT MSC under xenogeneic(xeno)-free culture conditions. Here we describe the successful use of human AB serum [10%(v/v)] as a culture supplement, as well as coating substrate for the expansion of these cells in microcarriers using (i) a spinner flask and (ii) a 500-mL mini-bioreactor (Applikon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.